Harrow (NASDAQ:HROW) Stock Price Up 7.7% – Time to Buy?

Harrow, Inc. (NASDAQ:HROW) shot up 7.7% during trading on Thursday . The stock traded as high as $36.24 and last traded at $36.15. 295,975 shares were traded during mid-day trading, a decline of 41% from the average session volume of 497,813 shares. The stock had previously closed at $33.55.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. B. Riley decreased their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Craig Hallum lifted their target price on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. Finally, Lake Street Capital lifted their price objective on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, October 4th.

Harrow Trading Up 7.6 %

The business’s 50 day moving average price is $41.15 and its two-hundred day moving average price is $37.54. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -38.41 and a beta of 0.69.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. First Turn Management LLC acquired a new position in Harrow in the third quarter valued at about $14,683,000. JPMorgan Chase & Co. boosted its stake in Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after acquiring an additional 194,480 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Harrow in the 3rd quarter valued at $8,572,000. Charles Schwab Investment Management Inc. increased its holdings in Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after purchasing an additional 166,602 shares during the last quarter. Finally, Braidwell LP grew its holdings in Harrow by 47.9% during the third quarter. Braidwell LP now owns 439,638 shares of the company’s stock valued at $19,766,000 after purchasing an additional 142,450 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.